|
Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms. |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
Travel, Accommodations, Expenses - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
Travel, Accommodations, Expenses - Foundation Medicine |
|
|
Employment - Epic Sciences; Foundation Medicine |
Travel, Accommodations, Expenses - Epic Sciences; Foundation Medicine |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
Consulting or Advisory Role - Celsius Therapeutics |
Research Funding - Foundation Medicine |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Clovis Oncology; Daiichi Sankyo; Janssen; MORE Health; ORIC Pharmaceuticals |
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); ORIC Pharmaceuticals (Inst); Zenith Epigenetics (Inst) |
Travel, Accommodations, Expenses - Clovis Oncology; GlaxoSmithKline; ORIC Pharmaceuticals |
|
|
Honoraria - Clovis Oncology; Novartis |
Consulting or Advisory Role - Astellas Pharma; Bayer; BeiGene; Clovis Oncology; Janssen-Cilag; Novartis; Pfizer |
Speakers' Bureau - Janssen-Cilag; Pfizer |
Research Funding - Sanofi/Aventis (Inst) |
|
|
Honoraria - Bayer; Janssen Oncology |
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Clovis Oncology (Inst); Dendreon; Myovant Sciences; Roivant |
Research Funding - Clovis Oncology (Inst); Genzyme (Inst) |
|
|
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi |
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer; Curevac; ESSA (Inst); Janssen Oncology (Inst); Orion; Sanofi (Inst) |
Travel, Accommodations, Expenses - Janssen; MSD |
|
|
Employment - Clovis Oncology |
Stock and Other Ownership Interests - Clovis Oncology |
|
|
Employment - Clovis Oncology |
Stock and Other Ownership Interests - Clovis Oncology; United Health Group |
|
|
Employment - Clovis Oncology |
Stock and Other Ownership Interests - Clovis Oncology |
Consulting or Advisory Role - Redwood Bioscience |
|
|
Employment - Clovis Oncology |
Stock and Other Ownership Interests - Clovis Oncology |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
Honoraria - Foundation Medicine; Guardant Health; Sysmex |
Consulting or Advisory Role - Abbvie; AstraZeneca; DropWorks; GRAIL; Illumina; Inivata; Janssen; LOXO; Merck; Merck; Sysmex; Takeda |
Patents, Royalties, Other Intellectual Property - DFCI has a patent pending titled "Non-invasive blood-based monitoring of genomic alterations in cancer", on which I am a co-author. (Inst) |